Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

BACKGROUND: We showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.® (OctLAR(®)) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe polycystic liver disease (PLD) and liver growth...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Hogan, Marie C., Masyuk, Tetyana V., Page, Linda, Holmes, David R., Li, Xujian, Bergstralh, Eric J., Irazabal, Maria V., Kim, Bohyun, King, Bernard F., Glockner, James F., LaRusso, Nicholas F., Torres, Vicente E.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2012
Teme:
Clinical Science
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3433774/
https://ncbi.nlm.nih.gov/pubmed/22773240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfs152
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki